TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of locoregional recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of distant metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain of Procedure Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe exacerbations rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emergency room visit for respiratory symptoms rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospitalization for respiratory symptoms rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Injection-Related Adverse Event Rate Per Year
Endpoint domain: Adverse events/effects
Primary endpoint: Panenteric mucosal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall changes in spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall change in muscle volume of the medial gastrocnemius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall changes in gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time Line Follow Back
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrimination between healthy and CRS subtypes based on SNOT 22 questionnaire results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination between healthy and CRS subtypes based on sensor response (electrical resistance measurements)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescents' perceptions and beliefs in sexual and reproductive health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experiences in teenage pregnancy and motherhood
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Family planning and support structures
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Area Under the Concentration-time Curve of BI 705564 in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 705564 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with disease specific complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contamination rate on surgical glove
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Eligible Participants Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Community ambulation using Step Activity Monitor (SAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait analysis (GaitRite system) including dual task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survivorship estimates
Endpoint domain: Mortality/survival
Primary endpoint: HBV DNA level < 10E4 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in International Restless Legs Syndrome Study Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects with mild to moderate Lupus flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKI-stadium 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of Antibody Against Protein D (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Developed Acute Kidney Injury Within 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax (the Maximum Observed Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (the Time to Maximum Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-8h (the Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of allergic reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Threshold reactive dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific IgEs for peanut components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of tree nuts and/or legumes allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability measured as number of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measurements of autonomic nervous system activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Latency of pupil response to light stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of pupil response to light stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of days alive and without emergency readmissions
Endpoint domain: Mortality/survival
Primary endpoint: Pain Scores (Verbal Numerical Rating Scale; VNRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With the Indicated Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormalities in Vital Signs, Electrocardiogram (ECG) and Clinically Significant Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcome Measurement Information System (PROMIS) Global Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Combined incidence of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Lersivirine plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rifabutin plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-O-desacetyl-rifabutin plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Chemistry Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematology Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Heart Rate Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of benign vs. malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of different malignant tumor types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0-6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: High serum ferritin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Composite of Major Bleeding and Clinically-relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Daily frequency of self-monitoring blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of days conducted at least 4 tests per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Average Sleep Continuity Profile
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Overall Average Sleep Efficiency (%)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Overall safety of BGF, GFF, and Symbicort MDI
Endpoint domain: Adverse events/effects
Primary endpoint: Primary cutaneous irritation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tolerability of GSK1940029 as assessed by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Surgeon assessment of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Re-hospitalization for Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Present Pain Intensity Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in intraabdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of daily walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colonisation of the catheter surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: retrieved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Distance from midclavicular point to postoperative nipple-areolar complex position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t: Area under the plasma concentration-time curve from time zero to last measurable plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AmtCUM: Cumulative Amount of Drug excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients completing anti-tuberculosis treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sleep data
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Circadian rhythm
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Signal quality loss (dropout rate)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline on the score of the Pelvic Floor Distress Inventory-short form 20 (PFDI-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dental health evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pathological complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biomarkers of cytoprotective activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for E7386
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for E7386
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of localization of the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oculomotor evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Posturography test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual dynamic acuity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local control time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative tests of facial and ocular demodicosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: median transfusion of packed red cells per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median Distance Skin to Epiglottis (mDSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity index for PSoriatic Arthritis (DAPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of attempted and completed suicides
Endpoint domain: Mortality/survival
Primary endpoint: Global Prevalence of ATTR-CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Clinician-Administrated PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and Social Adjustment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Frequency of nonspecific symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trunk Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trunk Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose uptake in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Vancouver Scar Scoring (VSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Agreement in the Detection of High-risk HPV Type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Wake Time (TWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Nighttime Injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function assessed by glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Degree of elbow extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on CBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effect on biochemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Abstinence or Moderate Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cortical GABA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed bimekizumab (BKZ) plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the BKZ plasma concentration-time curve from time zero to last quantifiable concentration (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the BKZ plasma concentration-time curve from time zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average daily sunlight exposure time to first prodromal symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function as determined by NIH Toolbox Picture Vocabulary Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Function as determined by NIH Flanker Inhibitory Control and Attention Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Function as determined by NIH List Sorting Working Memory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Function as determined by NIH Dimensional Change Card Sorting Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Function as determined by NIH Pattern Comparison Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Upper limb motor score in Fugl-Meyer assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of CD3/CD4/CD8 Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Grades II to IV aGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety of CD 34+ autologous progenitor cells introduction
Endpoint domain: Adverse events/effects
Primary endpoint: Surgeon and patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anti-proliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Maximal Cystometric Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in histological injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell Response to Peptide Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Predictive value of Apparent Diffusion Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Electroencephalogram changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of retinal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing of target fissure on the heel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Work of breathing indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of occult N2/3 metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: femoral component rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Days Abstinent From Alcohol Use During Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Days Abstinent From Alcohol Use During 6-month Follow-up Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State 2 respiration (GM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: State 3 respiration (GM3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: State 4 respiration (4o)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Residual Oxygen Consumption (ROX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggregate Focus Quality Measure order rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of responders and seizure free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CPC score of 1 or 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-hospitalization rate for any cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Circumcision uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: small, dense low density lipoprotein (LDL) subfractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychological anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Persistence of ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serial heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wound Healing/Scar Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment Success According to IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency domain analysis QEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time domain analysis QEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Power domain analysis QEEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of ASN-002 related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Microscopic clearance of the injected Target basal cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Variation in bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phototherapy usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Probability of variants being pathogenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes